Cipla Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.08 lakh crore. The company reports a net profit margin of 12%. Revenue grew +3.5% year-over-year. Promoter holding stands at 31.1%, with FII participation at 45%.
Most stocks in the same industry are struggling (sector — most peers below EMA20). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Yesterday's candle shape suggests sellers took control (⚠️ Doji — bearish pattern detected). The overall market is in a downtrend — all trades carry higher risk right now (BEAR MARKET regime, reduced confidence). Above-average delivery percentage suggests real buying, not just speculation (delivery 58%). Price is right at the level where the most trading happened recently — strong support (Volume POC ₹1,332). Early convergence forming: 3 signals are starting to align; watch for confirmation from the remaining signals before adding full position size.
Cipla Limited scores 27/100 (Weak Research Signal). The strongest signals are Momentum (9/100) and Volume Profile (8/100). The weakest dimension is Institutional Activity (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.